![Barbara Wan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Barbara Wan worked as VP-Project Leadership Research & Development at Cyteir Therapeutics, Inc. from 2020 to 2022.
Prior to that, she worked as Vice President-Project & Portfolio Management at Casebia Therapeutics LLC.
Dr. Wan holds a doctorate degree from Brandeis University.
| Sociétés | Poste | Fin |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2022 |
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
Brandeis University
 Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cyteir Therapeutics, Inc.
 Cyteir Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage oncology company | Health Technology |
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Discovers, develops and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders, autoimmune disease | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
